Oculis Holding 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, good afternoon. Welcome to Guggenheim 3rd Annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. Our next presenting company is Oculis Holding. From the company, we have Chief Executive Officer Riad Sherif. Riad, why don't you make some opening comments, tell us about the company, the programs that you have, some of the upcoming milestones, and then we'll go into the Q&A.
Thank you, Yatin. Thank you very much for inviting us. So, Oculis is a biopharma company focusing on neuro-ophthalmology, or neuroprotection company, actually. It has also, at the same time, a product which is reading out very soon in precision medicine in ophthalmology, which is called licaminlimab. If I go one by one, so two late-stage assets, privosegtor, which is really the midterm value driver, driven by three programs. The first is in optic neuritis, a disease which is an orphan indication, often a complication of MS without any treatment, and we are talking really about young adults. The second indication is NAION, which is also an orphan indication.
Yeah. In fact, this indication is actually increasing because of complications of other therapies, as you may know.
And the third indication is acute MS relapse, where the treatment will be treatment of the flares of any acute MS relapse. With licaminlimab, as I said, it is a precision medicine genotype-based development focusing on a subset of population which represent 1.5 million patients, which is already huge, and it's reading out in a matter of weeks. In terms of upcoming milestones, I would say the first milestone which is upcoming is the IND for the neuro indication. We submitted already, and we are waiting for the confirmation. This should come in the upcoming days, weeks. Then we have an R&D Day planned, December 8th, and then we have the top-line result.
During the R&D Day, we will be able to give an update on the execution of PIONEER-1.
fine-tune the timing for PREDICT-1, and explaining really the, I would say, the blueprint of multiple indications we are going to develop with privosegtor.
Got it. Very good then. Let's start with licaminlimab, the anti-TNF drops that you have. Can you maybe put in perspective the phase II data that you have generated? This is, I think, going to become much more of a central focus for investors because you're going to get data relatively soon. So walk us through the phase II data, then talk about the PREDICT-1 study that's going to read out. What is a good data? What would you like to see there?
Yeah. So licaminlimab is a TNF inhibitor, anti-inflammatory, anti-necrotic.
Yeah. Is a fragment of the antibody which has a benefit of having high concentration and good ocular tissue penetration.
And it comes with really something very unique, which is a biomarker which allows us to select patient who hyper-respond to the TNF inhibition. Product went into three phase IIs, two in symptom, one in sign. The most recent in symptom showed in an exploratory manner that TNFR1 patient showed much better response in symptoms than all-comers.
And really multiple. In most recent trial in signs as well, we saw that patient, it was pre-specified secondary endpoint, patient TNFR1 in signs improved much more than all-comers. It's a matter, just to give a magnitude, in sign, it was like five times what we saw in all-comers, six times with what we saw in the best phase III from the competition. So really meaningful response versus what we see in our all-comers and in all other product.
Got it. In terms of PREDICT is a study in symptoms, and we expect as well to see much better response in terms of efficacy, but also in terms of high responders, like patient who are responding with more than 20 point vis-à-vis all-comers.
Therefore, expectation from PREDICT-1 is really, we are doing a precision medicine, and the assumption is to have a precision medicine type of response, which should be higher than what we see in our all-comers and what we see with the competition.
Got it. In this study, you recently completed enrollment of 176 patients. First question is, what percentage are TNFR1, with the TNFR1 genotype?
Yeah. And then you mentioned about the efficacy on the primary endpoint, which is global ocular discomfort scale, and then the responder rate.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
